SD Biosensor Inc (137310) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SD Biosensor Inc (137310) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.90 Billion ≈ $10.09 Million USD) by net assets (₩3.07 Trillion ≈ $2.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is SD Biosensor Inc's balance sheet to measure how much of total assets are equity-financed.
SD Biosensor Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SD Biosensor Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
SD Biosensor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SD Biosensor Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Lihang Technology Co.Ltd.
SHG:603261
|
N/A |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
0.012x |
|
Sterling and Wilson Renewable Energy Limited
NSE:SWSOLAR
|
-0.766x |
|
Guangdong Sunwill Precising Plastic Co Ltd
SHE:002676
|
0.061x |
|
Shanghai Metersbonwe Fashion&Accessories Co Ltd
SHE:002269
|
-0.519x |
|
Hebei Jianxin Chemical Co Ltd
SHE:300107
|
0.002x |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
0.146x |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
0.056x |
Annual Cash Flow Conversion Efficiency for SD Biosensor Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of SD Biosensor Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SD Biosensor Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.93 Trillion ≈ $1.99 Billion |
₩156.53 Billion ≈ $106.08 Million |
0.053x | +162.38% |
| 2023-12-31 | ₩2.83 Trillion ≈ $1.92 Billion |
₩-242.32 Billion ≈ $-164.22 Million |
-0.086x | -128.33% |
| 2022-12-31 | ₩2.95 Trillion ≈ $2.00 Billion |
₩890.23 Billion ≈ $603.30 Million |
0.302x | -46.10% |
| 2021-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩1.23 Trillion ≈ $836.90 Million |
0.560x | -14.29% |
| 2020-12-31 | ₩757.55 Billion ≈ $513.38 Million |
₩495.38 Billion ≈ $335.71 Million |
0.654x | +5650.64% |
| 2019-12-31 | ₩137.91 Billion ≈ $93.46 Million |
₩-1.62 Billion ≈ $-1.10 Million |
-0.012x | -- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more